Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01898806 · ClinicalTrials.gov registry record · Phase 4
Intralesional Steroids in the Treatment of Alopecia Areata
A Phase 4 study, sponsored by Columbia University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 11
- Enrollment target
NCT01898806 is a Phase 4 study that was terminated before completion, run by Columbia University. The registered enrollment target is 11 participants.
The verdict
NCT01898806, a Phase 4 study, was terminated before completion, sponsored by Columbia University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 11 participants
- Enrollment target
Study Summary
This study aims to determine the frequency of response to treatment with 3 concentrations of IL TAC, 2.5mg/ml, 5mg/ml or 10mg/ml as well as the duration of response and incidence of side effects compared to treatment with placebo (sterile saline solution). After the 1st 6 months, nonresponders or partial responders may be treated for 6 months with open label triamcinolone at the dose deemed appropriate by the investigator. The investigators will also perform skin biopsies of the scalp and draw blood at selected time points in order to examine the immunohistochemical/pathological response in scalp hair follicles and the systemic circulation to treatment with IL TAC for alopecia areata.
Interventions
- DRUG Intralesional Triamcinolone 10 mg/ml
- DRUG Intralesional Triamcinolone 2.5 mg/ml
- DRUG Intralesional Triamcinolone 5 mg/ml
- DRUG Intralesional Saline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2011-09 |
| Est. Completion | 2018-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01898806
The ClinicalTrials.gov registry entry for NCT01898806 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Intralesional Triamcinolone 10 mg/ml is the first listed.
NCT01898806 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01898806 about?
NCT01898806 is a clinical study titled "Intralesional Steroids in the Treatment of Alopecia Areata". This study aims to determine the frequency of response to treatment with 3 concentrations of IL TAC, 2.5mg/ml, 5mg/ml or 10mg/ml as well as the duration of response and incidence of side effects compared to treatment with placebo (sterile saline solution). After the 1st 6 months, nonresponders or pa...
What is the current status of trial NCT01898806?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 11 participants. The study started on 2011-09. Estimated completion is 2018-01.
What interventions are being tested in trial NCT01898806?
The interventions under investigation include: Intralesional Triamcinolone 10 mg/ml (DRUG), Intralesional Triamcinolone 2.5 mg/ml (DRUG), Intralesional Triamcinolone 5 mg/ml (DRUG), Intralesional Saline (DRUG).
Who is sponsoring clinical trial NCT01898806?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.